Shiga, Japan

Kyoichi Ideguchi

This inventor holds 3 USPTO granted patents. Top assignee: Nippon Shinyaku Company, Ltd.. Active years: 1980-2001.


% Patents Active = 100.0

Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 21(Granted Patents)


Location History:

  • Kyoto, JP (1980)
  • Shiga, JP (1999 - 2001)

Company Filing History:


Years Active: 1980-2001

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Kyoichi Ideguchi: Innovator in Pharmaceutical Chemistry

Introduction

Kyoichi Ideguchi is a prominent inventor based in Shiga, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for medical applications. With a total of 3 patents to his name, Ideguchi continues to push the boundaries of science and medicine.

Latest Patents

Among his latest patents, Ideguchi has developed a pharmaceutical composition that includes a heterocyclic derivative, which is crucial for various medical treatments. Another notable patent involves derivatives of pyrimidine aimed at treating acute cerebrovascular disorders. These inventions highlight his commitment to addressing critical health issues through innovative solutions.

Career Highlights

Kyoichi Ideguchi is currently associated with Nippon Shinyaku Company, Ltd., where he applies his expertise in pharmaceutical research and development. His work has not only advanced the company's portfolio but has also contributed to the broader field of medicine.

Collaborations

Throughout his career, Ideguchi has collaborated with esteemed colleagues such as Yojiro Ukai and Shoichi Chokai. These partnerships have fostered a collaborative environment that enhances innovation and accelerates the development of new therapeutic solutions.

Conclusion

Kyoichi Ideguchi stands out as a dedicated inventor in the pharmaceutical industry. His innovative patents and collaborative efforts continue to make a significant impact on medical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…